In the EU in 2020, lung cancer was the second-most common cancer among males and the third-most common among females, with an estimated incidence of 97.2 per 100 000 males and 43.9 per 100 000 females. Among all cancers, it has been the leading cause of death for both sexes since 2017. Screening using low-dose computed tomography (LDCT) can detect lung cancer early, reducing mortality by at least 20%.

SOLACE aims to improve lung cancer screening across Europe by supporting the implementation and optimisation of LDCT screening programmes, provide a modular framework (toolbox) that tailors screening approaches to national or regional needs so as to address health inequalities, increase life expectancy, improve quality of life and ensure cost-effectiveness, and bring together stakeholders to design, plan and implement sustainable lung cancer screening.